CClinicalTrials.gg
CompletedNCT00940537NAFLDUpdated Jun 15, 2018Results posted

Magnetic Resonance Spectroscopy (MRS) Validation Study in Individuals With Nonalcoholic Fatty Liver Disease (NAFLD)

An observational study in Liver Diseases, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-15.

Sponsored by Washington University School of Medicine · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
14
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to see how effective the investigators' optimized magnetic resonance spectroscopy (MRS) sequence in quantifying hepatic triglyceride content (HTGC) to enhance MRS as a diagnostic tool in non-alcohol fatty liver disease (NAFLD).

Read the detailed description

One way to gauge MRS as an effective diagnostic tool is by looking at the reproducibility of the liver fat measurements on subjects by calculating the coefficient of variation (CV). This study assesses the modified MRS sequence, using both breath holds and free breathing. The HTGC levels are measured twice in the same individuals on two independent events separated by 10 minutes. Subjects are then given a high fat, high carbohydrate meal of Pizza Hut pizza, Pepsi, and Oreo cookies. Two hours after eating the meal, the subjects return to the scanner and repeat all MRS scans.

02

Conditions studied

  • Liver Diseases

Keywords

  • Obese
  • MRS
  • hepatic triglyceride content
  • MR spectroscopy
03

In context

Liver Diseases

2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.

This study's enrollment of 14 is below the median of 167 across 681 observational studies indexed under Liver Diseases.

Browse Liver Diseases studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,765 studies on the registry; 271 are open to participants now.

Of its 324 completed or terminated interventional studies of FDA-regulated products, 212 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

St. Louis community

Inclusion criteria

  • Obese

Exclusion criteria

Exclusion Criteria:

  • Diabetes
  • Pregnant
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
14 participants (actual)

Groups and cohorts

  • NAFLD

    Non-diabetic, obese with diagnosed NAFLD (HTGC greater or equal to 5.5%)

  • Non-NAFLD

    Non-diabetic, obese with no previous diagnosis of NAFLD

06

What researchers measure

Primary outcomes

  1. The Reproducibility of the Hepatic Triglyceride Content Measurement by MRS.

    We compared three 1H-Magnetic Resonance Spectroscopy sequences: A Standard Siemens sequence, and an optimized sequence with either breath-holds or free-breathing. Repeat scans were done with the subject briefly removed from and returned to the scanner between scans. The results given are coefficients of variation of the triglyceride signal divided by the water signal.

    Time frame: 6 months

Secondary outcomes

  1. The Hepatic Triglyceride Content Pre- and Post-prandial.

    We compared the intrahepatic triglyceride content in subjects after a 12 hour fast and 2 hours after eating a high fat, high carbohydrate meal. The measure reported here is for the pre and post prandial results given as the ratio of triglyceride signal to water signal. After showing its reliability, we chose to use the results from the optimized breath-hold sequence.

    Time frame: after a 12 hour fast and 2 hours post-prandial

  2. T2 (Spin-spin Relaxation Time) Ratios of Triglyceride/Water

    T2 (spin-spin relaxation time) ratios of triglyceride/water using optimized PRESS sequences

    Time frame: baseline cross-sectional measurements

07

Results

Posted May 13, 2010

Participant flow

Subjects were recruited through the Center for Human Nutrition (CHN) beginning in July, 2009. Many had previously been enrolled in other CHN studies. The final subject was tested in December, 2009.

Participant flow — Overall Study
MilestoneNAFLDNon-NAFLD
Started59
Completed59
Not completed00

Outcome measures

PrimaryThe Reproducibility of the Hepatic Triglyceride Content Measurement by MRS.

We compared three 1H-Magnetic Resonance Spectroscopy sequences: A Standard Siemens sequence, and an optimized sequence with either breath-holds or free-breathing. Repeat scans were done with the subject briefly removed from and returned to the scanner between scans. The results given are coefficients of variation of the triglyceride signal divided by the water signal.

Time frame:
6 months
Reported as:
Mean · coefficient of variation
The Reproducibility of the Hepatic Triglyceride Content Measurement by MRS.
coefficient of variationNAFLDNon-NAFLD
Siemens sequence13.0 ± 9.623.5 ± 1.1
Optimized sequence4.4 ± 3.99.7 ± 0.1
SecondaryThe Hepatic Triglyceride Content Pre- and Post-prandial.

We compared the intrahepatic triglyceride content in subjects after a 12 hour fast and 2 hours after eating a high fat, high carbohydrate meal. The measure reported here is for the pre and post prandial results given as the ratio of triglyceride signal to water signal. After showing its reliability, we chose to use the results from the optimized breath-hold sequence.

Time frame:
after a 12 hour fast and 2 hours post-prandial
Reported as:
Mean · ratio
The Hepatic Triglyceride Content Pre- and Post-prandial.
ratioNAFLDNon-NAFLD
fasting30 ± 128 ± 7
post-prandial27 ± 98 ± 7
Statistical analysis
  • NAFLD vs Non-NAFLD · t-test, 2 sided · p = .097 (a priori threshhold for significance was set at p\<0.05.)this was a paired t-test
SecondaryT2 (Spin-spin Relaxation Time) Ratios of Triglyceride/Water

T2 (spin-spin relaxation time) ratios of triglyceride/water using optimized PRESS sequences

Time frame:
baseline cross-sectional measurements
Reported as:
Mean · ratio
T2 (Spin-spin Relaxation Time) Ratios of Triglyceride/Water
ratioAll Subjects
Low IHTG0.9 ± 0.1
Medium IHTG1.1 ± 0.1
High IHTG1.1 ± 0.1
Statistical analysis
  • All Subjects · t-test, 2 sided · p = 0.006 (This p-value compares the low IHTG (\<5%) subjects to those with medium levels of IHTG (5 - 10%). The a priori threshold for statistical significance was p\<0.05.)
  • All Subjects · t-test, 2 sided · p = <0.0001 (The a priori threshold for statistical significance was p\<0.05.)
  • All Subjects · t-test, 2 sided · p = .93 (The a priori threshold for statistical significance was set at p\<0.05.)

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NAFLD—0/5 (0%)0/5 (0%)
Non-NAFLD—0/9 (0%)0/9 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)NAFLDNon-NAFLDTotal
<=18 years000
Between 18 and 65 years5813
>=65 years011
Age, Continuous
Age, Continuous(years)NAFLDNon-NAFLDTotal
Mean43 ± 1346 ± 1245 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)NAFLDNon-NAFLDTotal
Female448
Male156
Region of Enrollment
Region of Enrollment(participants)NAFLDNon-NAFLDTotal
United States5914
08

Study locations

1 site
  • Barnes Jewish Hospital
    Saint Louis, Missouri 63110, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00940537
Lead sponsor
Washington University School of Medicine
Responsible party
Sponsor
First posted
Jul 16, 2009
Start date
Jun 2009
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
May 13, 2010
Last update
Jun 15, 2018

Study contacts

Samuel Klein, M.D.
principal investigator · Washinton University in St. Louis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion